On Apr. 14, 2026, Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology across its operations as it looks to keep pace with rapid expansion in the obesity drug market. The Danish company announced that it would use AI to analyze complex datasets, identify promising drug candidates and reduce the time between research and patient application.

President and CEO Mike Doustdar said the partnership would help discover new treatments for obesity and diabetes and “bringing them to market faster than ever before.” “There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” Doustdar said. “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.”

The technology will also allow the company to streamline manufacturing, supply chain and distribution and corporate operations, with AI expected to be fully integrated by the end of the year, according to the announcement.